Astellas Pharma has announced the availability of regadenoson (Lexiscan injection) for use as a pharmacologic stress agent. Regadenoson was co-developed by CV Therapeutics and, according to the manufacturer, is the first A2A adenosine receptor agonist to be used in myocardial perfusion imaging. The new agent will be used for patients undergoing cardiac stress tests who are unable to exercise for medical reasons.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
